Phase II Randomized Trial of 2 Versus 5 Fraction Prostate Stereotactic Ablative Radiotherapy for Intermediate Risk Prostate Cancer
This study, called ADAPT-2, is looking at men with a common type of prostate cancer that hasn't spread. It compares two ways of giving a special type of radiation therapy called SABR. One way is the standard 5 treatment sessions, and the other is a new approach with only 2 sessions. The main goal is to see if having fewer sessions reduces side effects, improves quality of life, and is just as effective at controlling the cancer. Both methods use special techniques to protect nearby organs. We also explore how a new computer program (AI) might help guide treatment in the future. The study aims to find the best and most convenient treatment for patients.
Em resumo
Sobre o que é este estudo?
Prostate cancer is quite common among men, and thankfully, if it hasn't spread, there are often several ways to treat it effectively. One modern treatment option is called Stereotactic Ablative Radiotherapy, or SABR for short. This is a very precise type of radiation therapy where a small number of strong radiation doses (usually 5 to 7 sessions) are given directly to the prostate. Many studies have shown that 5-session SABR works very well, often as good as other treatments, and can lead to fewer side effects and a better quality of life compared to surgery.
Now, imagine if we could get the same excellent results, but with even fewer treatment sessions. That's what this study is exploring! It's comparing the standard 5-session SABR with a new approach that uses only 2 sessions. The hope is that fewer sessions could mean even better cancer control, fewer side effects, and be much more convenient for patients. While some smaller studies suggest 2-session SABR might be effective and well-tolerated, we don't yet have enough information comparing it directly to 5-session SABR to know which is truly better.
To make sure this treatment is as safe as possible, both the 2-session and 5-session approaches in this study will use special techniques. This includes continuously tracking the prostate gland during treatment to ensure the radiation hits the right spot, and using a special gel (called SpaceOAR Hydrogel) placed between the prostate and the bowel to protect nearby organs and reduce side effects. The study will also be looking at a new computer program that uses artificial intelligence (AI) to see if it could help guide radiation treatment even more accurately in the future. This AI part is like a trial run; the AI won't directly guide your treatment during the study, but researchers will see if it could be useful later on.
Pontos principais
- Compares 2 versus 5 radiation sessions for prostate cancer.
- Aims to find out which approach has fewer side effects and a better quality of life.
- Uses advanced techniques to protect nearby organs during treatment.
- Helps researchers understand the best way to treat intermediate-risk prostate cancer.
- Investigating if AI can improve future radiation planning.
- Participation involves close monitoring for long-term health.
Quem pode ser elegível?
This study is for men aged 18 or older who have been diagnosed with certain types of prostate cancer that doctors consider to be 'intermediate risk' and that hasn't spread to other parts of the body. You would need to be generally healthy enough to undergo the treatments and follow-up appointments, with an expected lifespan of more than 5 years.
You cannot join this study if your cancer is considered more advanced, for example, if it has spread to lymph nodes or other organs, or if it's a very aggressive type (Gleason score 8 or higher, or PSA over 20). Your prostate size also needs to be below a certain limit. You'll need to be willing to have small markers placed in your prostate and a special gel placed to protect your bowel during treatment.
If you're already receiving hormone therapy (Androgen Deprivation Therapy, or ADT), you might still be able to join, depending on when your treatment started and if it's possible to complete the radiation part of the study before you finish 6 months of ADT. Your doctor will carefully review all your medical information to see if this study is a good fit for you.
Este estudo pode ser adequado para você?
Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.
- Você tem 18 anos ou mais?
- Have you been diagnosed with 'intermediate risk' prostate cancer that hasn't spread?
- Are you generally healthy enough for treatment and follow-up for several years?
- Are you willing to have small markers and a special gel placed before radiation?
- Do you have a life expectancy of more than 5 years?
O que envolve a participação?
If you decide to join this study, you will be randomly assigned to receive either 2 or 5 sessions of prostate SABR. Before your treatment begins, you will have small markers placed in your prostate (called fiducial markers) and a special gel (SpaceOAR Hydrogel) injected between your prostate and bowel – these help ensure accurate treatment and protect nearby organs. You will then receive your assigned radiation treatment in either 2 or 5 sessions over a period of 1 to 2 weeks. Throughout the study, you'll have regular check-ups, which may include blood tests (like PSA), scans, and questionnaires to monitor your recovery, side effects, and overall quality of life. The total duration of follow-up for this study will be several years, as researchers want to understand the long-term effects of the treatments.
Riscos e benefícios potenciais
Localizações (1)
- BC Cancer Radiation OncologyCódigo postal verificadoVictoria, Canada· Recrutamento
Perguntas frequentes
What is SABR?
SABR (Stereotactic Ablative Radiotherapy) is a very precise type of radiation treatment for cancer that uses strong, focused beams to target the tumour with fewer, higher doses.
What does 'intermediate risk' prostate cancer mean?
It means your prostate cancer has certain features that put it at a moderate chance of growing or spreading, but it's not yet considered high-risk or spread outside the prostate.
Will I get to choose between 2 or 5 sessions?
No, you will be randomly assigned to receive either 2 or 5 sessions, like flipping a coin. This helps make the study fair and scientific.
What is the 'rectal spacer'?
It's a special gel (SpaceOAR Hydrogel) placed between your prostate and your bowel to create a small gap, protecting your bowel from radiation and reducing side effects.
What is the role of AI in this study?
Researchers are testing a new AI computer program to see if it could help target radiation more accurately in the future, but it won't be used to guide your actual treatment in this study.
Como saber mais
Cathy Tran
Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.
Interessado em participar?
Discussão
Discussão da comunidade
Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.